Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model-Reference-Cited by-同舟云学术

Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model

Published:2020-01-01 Issue:1 Volume:43 Page:93-101
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Maeda Hitoshi¹,Minayoshi Yuki¹,Ichimizu Shota¹,Mizuta Yuki¹,Nagasaki Taisei¹,Matsusaka Kotaro¹,Oshiro Shun¹,Oniki Kentaro²,Saruwatari Junji²,Ishima Yu³,Watanabe Hiroshi¹,Otagiri Masaki⁴,Maruyama Toru¹

Affiliation:

1. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University

2. Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University

3. Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University

4. Faculty of Pharmaceutical Sciences and DDS Research Institute, Sojo University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/43/1/43_b19-00599/_pdf

Reference38 articles.

1. 1) Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, 393, 1453–1464 (2019).

2. 2) Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol. Hepatol., 1, 56–67 (2016).

3. 3) Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers, 4, 16 (2018).

4. 4) Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149, 389–397.e10 (2015).

5. 5) Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J. Hepatol., 70, 294–304 (2019).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders;Advanced Drug Delivery Reviews;2024-04

2. Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis;Pharmaceuticals;2024-02-19

3. Albumin-based Drug Delivery System Targeting Mannose Receptors and Its Application to Medical Treatments;YAKUGAKU ZASSHI;2023-11-01

4. Insights on drug and gene delivery systems in liver fibrosis;Asian Journal of Pharmaceutical Sciences;2023-03

5. Cholestyramine Modulates Non-Alcoholic Steatohepatitis Induced by Methionine and Choline Deficiency in Rats: Cross-linking AGEs, MIP2, EMR1 and Adiponectin.;Egyptian Journal of Chemistry;2023-01-10